-
Takeda Opens R&D Cell Therapy Mfg. Facility in Boston
contractpharma
September 16, 2020
Will support expansion of next-generation clinical programs, including five collaborative oncology cell therapy programs entering trials.
-
Sotio Acquires Rights to BOXR Cell Therapy Platform
contractpharma
September 01, 2020
Sotio, a clinical stage immuno-oncology company owned by PPF Group, has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors.
-
India gives nod to cell therapy for Critical Limb Ischemia (CLI)
europeanpharmaceuticalreview
August 25, 2020
Stempeucel®, a cell therapy for the treatment of Critical Limb Ischemia (CLI), has been approved for commercial use in India by the Drug Controller General.
-
Orca Bio raises $192m to support cell therapies development
pharmaceutical-technology
June 19, 2020
US-based biotechnology firm Orca Bio has raised $192m in a Series D financing round to support the development of cell therapies intended to provide an alternative for standard bone marrow transplants.
-
Lineage Cell Therapeutics to apply allogeneic dendritic cell therapy programme to Covid-19 vaccine d
pharmaceutical-business-review
May 08, 2020
Lineage Cell Therapeutics, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
-
RoosterBio, Senti Biosciences Partner on Cell Therapy
contractpharma
March 23, 2020
Collaboration leverages cGMP clinical systems to accelerate gene modified cell therapy for solid tumors.
-
Cellenkos to trial cell therapy for CoV-ARDS
pharmaceutical-technology
March 19, 2020
Cellenkos has filed a proposal with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase I / II clinical trial of CK0802 to treat Covid-19 ...
-
Charles River Laboratories to acquire HemaCare for $380m
pharmaceutical-technology
December 18, 2019
Charles River Laboratories International has signed a definitive agreement to acquire cellular products developer HemaCare for a cash consideration of approximately $380m.
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
biospectrumasia
August 15, 2019
Implied total company value of up to $1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRo
-
ReNeuron climbs on updated vision loss cell therapy data
fiercebiotech
April 28, 2019
ReNeuron has reported further improvements in the vision of patients treated with its cell therapy. The mean increase in visual acuity across the three retinitis pigmentosa (RP) patients now stands at 23 letters, well above the level deemed clinically mea